Literature DB >> 20401600

[Amyotrophic lateral sclerosis: management of bulbar symptoms].

P Kraft1, M Beck, A Grimm, C Wessig, K Reiners, K V Toyka.   

Abstract

Symptomatic treatment of amyotrophic lateral sclerosis (ALS) is relevant in preventing complications and improving quality of life as long as curative therapies are still out of sight. About one third of ALS patients show disabling problems associated with dysarthria, dysphagia, sialorrhea, and a pseudobulbar affective disorder already in the early stages of ALS. A multidisciplinary approach is the cornerstone of symptomatic treatment of bulbar and pseudobulbar ALS features. Except for riluzole randomized controlled trials are lacking. Here, we review the current views with regard to epidemiology, pathophysiology, diagnosis, and practical aspects of treating bulbar and pseudobulbar symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401600     DOI: 10.1007/s00115-010-3008-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  71 in total

Review 1.  The management of motor neurone disease.

Authors:  P N Leigh; S Abrahams; A Al-Chalabi; M-A Ampong; L H Goldstein; J Johnson; R Lyall; J Moxham; N Mustfa; A Rio; C Shaw; E Willey
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

2.  Poststroke depression and emotional incontinence: correlation with lesion location.

Authors:  J S Kim; S Choi-Kwon
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

3.  The control of oral secretions in bulbar ALS/MND.

Authors:  A R Newall; R Orser; M Hunt
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

4.  Nutritional status is a prognostic factor for survival in ALS patients.

Authors:  J C Desport; P M Preux; T C Truong; J M Vallat; D Sautereau; P Couratier
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis.

Authors:  Jesús Sancho; Emilio Servera; Juan Díaz; Julio Marín
Journal:  Chest       Date:  2004-04       Impact factor: 9.410

6.  Xaliproden in amyotrophic lateral sclerosis: early clinical trials.

Authors:  Lucette Lacomblez; Gilbert Bensimon; Patrice Douillet; Valérie Doppler; François Salachas; Vincent Meininger
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-06

7.  Progressive sudomotor dysfunction in amyotrophic lateral sclerosis.

Authors:  M Beck; R Giess; T Magnus; I Puls; K Reiners; K V Toyka; M Naumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-07       Impact factor: 10.154

8.  Transdermal scopolamine for reduction of drooling in developmentally delayed children.

Authors:  D W Lewis; C Fontana; L K Mehallick; Y Everett
Journal:  Dev Med Child Neurol       Date:  1994-06       Impact factor: 5.449

9.  Treatment of pathologic laughing and weeping with amitriptyline.

Authors:  R B Schiffer; R M Herndon; R A Rudick
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

10.  Atropine drops for drooling: a randomized controlled trial.

Authors:  Gustavo G De Simone; Jorge H Eisenchlas; Marta Junin; Facundo Pereyra; Rafael Brizuela
Journal:  Palliat Med       Date:  2006-10       Impact factor: 4.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.